Gastric Adenocarcinoma
Conditions
Interventions
Three-drug perioperative chemotherapy regimens group (FLOT, etc.):None
Two-drug perioperative chemotherapy regimens group (CAPOX, SOX, FOLFOX, FLO, FP, etc.):None
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 18 years or older, male or female; 2. Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathological histology or cytology; 3. Tumor stage cT2-4bNanyM0; 4. ECOG PS score 0-2; 5. Expected survival >= 12 weeks; 6. Important organ functions meet the following requirements (no use of any blood components, cell growth factors, white blood cell enhancers, platelet enhancers, or anemia correction drugs within 14 days before the first neoadjuvant chemotherapy): (1) Absolute neutrophil count (ANC) >= 1.5*10^9/L; (2) Platelets >= 100*10^9/L; (3) Hemoglobin >= 9g/dL; (4) Serum albumin >= 2.8g/dL; (5) Total bilirubin 60mL/min; (7) Activated partial thromboplastin time (APTT) and international normalized ratio (INR) 50% in echocardiography before treatment; 7. No history of surgical resection; 8. Exclusion of peritoneal metastasis by laparoscopy (if clinically suspected); 9. Patients can understand the purpose of the trial, voluntarily participate and sign the informed consent form, are willing to complete the follow-up according to the protocol requirements, are conscious, and can answer questions correctly; 10. Patients can proficiently use smartphones to complete software download and project transmission feedback by themselves or with the help of relatives.
Exclusion criteria
Exclusion criteria: 1. Presence of distant metastasis (M1) before the trial; 2. BMI = 10% within 2 months before treatment; 3. PS score > 2; 4. Pregnant or lactating women; 5. Presence of chronic gastrointestinal diseases; 6. Unable to receive anti-tumor treatment due to patient refusal or organ dysfunction, complications, etc.; 7. Missing information on past medical history, laboratory tests, treatment, etc.; 8. Patients refuse to provide data or refuse to participate in the study; 9. Other situations that the researchers judge to be inappropriate for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life score; | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 excision rate;Tumor retraction grade;ypTNM;Adverse effects rate; | — |
Countries
China
Contacts
Public ContactWensheng Qiu
The Affiliated Hospital of Qingdao University
Outcome results
None listed